ATE526019T1 - Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen - Google Patents

Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen

Info

Publication number
ATE526019T1
ATE526019T1 AT01972917T AT01972917T ATE526019T1 AT E526019 T1 ATE526019 T1 AT E526019T1 AT 01972917 T AT01972917 T AT 01972917T AT 01972917 T AT01972917 T AT 01972917T AT E526019 T1 ATE526019 T1 AT E526019T1
Authority
AT
Austria
Prior art keywords
treating cell
cell proliferation
virus infections
proliferation disorders
viral infections
Prior art date
Application number
AT01972917T
Other languages
English (en)
Inventor
Rosen Neal
Srethapakdi Mary
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26915764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE526019(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE526019T1 publication Critical patent/ATE526019T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT01972917T 2000-07-28 2001-07-27 Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen ATE526019T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22141500P 2000-07-28 2000-07-28
US24526400P 2000-11-02 2000-11-02
PCT/US2001/023640 WO2002009696A1 (en) 2000-07-28 2001-07-27 Methods for treating cell proliferative disorders and viral infections

Publications (1)

Publication Number Publication Date
ATE526019T1 true ATE526019T1 (de) 2011-10-15

Family

ID=26915764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01972917T ATE526019T1 (de) 2000-07-28 2001-07-27 Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen

Country Status (8)

Country Link
US (1) US6946456B2 (de)
EP (1) EP1322307B1 (de)
JP (1) JP2004505044A (de)
KR (1) KR20030046397A (de)
AT (1) ATE526019T1 (de)
AU (2) AU9254801A (de)
CA (1) CA2417495C (de)
WO (1) WO2002009696A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439359B2 (en) * 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
WO2003037860A2 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
WO2003066005A2 (en) 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
WO2003079936A1 (en) * 2002-03-18 2003-10-02 Medtronic Ave Inc. Medical devices for delivering anti-proliferative compositions to anatomical sites at risk for restenosis
CA2481683A1 (en) * 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
MXPA06002997A (es) 2003-09-18 2007-02-08 Conforma Therapeutics Corp Novedosos compuestos heterociclicos como inhibidores- hsp90.
EP1670955A2 (de) * 2003-09-22 2006-06-21 Rosetta Inpharmatics LLC. Durchmusterungsverfahren zum auffinden synthetischer lethalität mittels rna-interference
AU2004309395C1 (en) 2003-12-23 2012-10-04 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
EP1817295B1 (de) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Hsp90-aktivität modulierende triazolverbindungen
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
AU2006230447A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
BRPI0608661A2 (pt) * 2005-04-07 2010-01-19 Conforma Therapeutics Corp formulaÇço farmacÊutica, uso de formulaÇço farmacÊutica, e, mÉtodo de preparaÇço de uma formulaÇço farmacÊutica
US7776849B2 (en) 2005-06-29 2010-08-17 Kyowa Hakko Kirin Co., Ltd. Benzenoid ansamycin derivative
JP5118039B2 (ja) 2005-08-18 2013-01-16 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
JP2009518302A (ja) * 2005-12-01 2009-05-07 コンフォーマ・セラピューティクス・コーポレイション アンサマイシン含有組成物
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
CA2653327A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
JP5465006B2 (ja) 2006-08-11 2014-04-09 ユニベルシテ・ドウ・ストラスブール キナーゼおよびｈｓｐ９０の阻害剤として有用な大環状化合物
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
MX2009008756A (es) 2007-03-01 2009-08-27 Chugai Pharmaceutical Co Ltd Compuesto macrociclico.
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
SG187502A1 (en) 2008-02-01 2013-02-28 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors
BRPI0924107A2 (pt) * 2008-11-28 2019-09-24 Novartis Ag inibidores de hsp90 para tratamento terapêutico
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
DE102009054302A1 (de) 2009-11-23 2011-05-26 Merck Patent Gmbh Chinazolinderivate
EP3141245A1 (de) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Verfahren zur behandlung von karzinomen
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
EP2560640A1 (de) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
DE102010046837A1 (de) 2010-09-29 2012-03-29 Merck Patent Gmbh Phenylchinazolinderivate
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3595955A (en) 1969-03-26 1971-07-27 Upjohn Co Geldanamycin and process for producing same
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
KR920000763A (ko) * 1990-06-06 1992-01-29 가와무라 요시부미 라디시콜 유도체, 그 제조방법 및 그의 항종양 활성
US5650430A (en) * 1990-06-06 1997-07-22 Sankyo Company, Limited Radicicol derivatives, their preparation and their anti-tumor activity
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5731343A (en) * 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
KR19990076764A (ko) * 1996-10-25 1999-10-15 히라타 다다시 래디시콜 유도체
CA2287387C (en) * 1997-05-14 2010-02-16 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
CA2367143A1 (en) * 1999-04-02 2000-10-12 Euro-Celtique S.A. Purine derivatives having phosphodiesterase iv inhibition activity
JP2002541255A (ja) 1999-04-09 2002-12-03 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物
US6335157B1 (en) * 1999-05-07 2002-01-01 The European Molecular Biology Laboratory Method based on localization of Hsp90 to the centrosome
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
JP2004504356A (ja) * 2000-07-20 2004-02-12 メルク　エンド　カムパニー　インコーポレーテッド Ｃ型肝炎ウイルスのプロセシングおよび複製の抑制
AU2002228772B2 (en) * 2000-11-02 2005-12-08 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors

Also Published As

Publication number Publication date
US6946456B2 (en) 2005-09-20
EP1322307A4 (de) 2008-08-13
WO2002009696A1 (en) 2002-02-07
CA2417495A1 (en) 2002-02-07
CA2417495C (en) 2013-04-30
KR20030046397A (ko) 2003-06-12
EP1322307B1 (de) 2011-09-28
US20030216369A1 (en) 2003-11-20
AU2001292548B2 (en) 2005-06-16
AU9254801A (en) 2002-02-13
JP2004505044A (ja) 2004-02-19
EP1322307A1 (de) 2003-07-02

Similar Documents

Publication Publication Date Title
ATE526019T1 (de) Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
DE60229059D1 (de) Proteomimetische verbindungen und verfahren
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DK1062226T3 (da) Nukleinsyreligander med høj affinitet mod komplementsystemets C5-protein
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
ATE315938T1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
DK1721979T3 (da) Sammensætninger og fremgangsmåder til forøgelse af knoglemineralisering
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
DE69931377D1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
WO2002069900A3 (en) Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
DE60039415D1 (de) Reovirus zur behandlung von zellulären proliferativen erkrankungen
ATE519862T1 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
DK1278868T3 (da) Muteret form af arginindeiminase
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
ATE290315T1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
EP1499190A4 (de) Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
BRPI0412441A (pt) método para estabilizar um crioprecipitado de proteìnas plasmáticas para ser submetido a um tratamento térmico de inativação viral
ATE128128T1 (de) Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one.
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties